420 related articles for article (PubMed ID: 34997254)
21. Nephrogenic systemic fibrosis: fibrotic plaques and contracture following exposure to gadolinium-based contrast media.
He A; Kwatra SG; Zampella JG; Loss MJ
BMJ Case Rep; 2016 Apr; 2016():. PubMed ID: 27073153
[No Abstract] [Full Text] [Related]
22. Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention.
Bäuerle T; Saake M; Uder M
Rofo; 2021 Sep; 193(9):1010-1018. PubMed ID: 33348385
[TBL] [Abstract][Full Text] [Related]
23. Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update.
Ramalho J; Semelka RC; Ramalho M; Nunes RH; AlObaidy M; Castillo M
AJNR Am J Neuroradiol; 2016 Jul; 37(7):1192-8. PubMed ID: 26659341
[TBL] [Abstract][Full Text] [Related]
24. [Nephrogenic fibrosing dermopathy or nephrogenic systemic fibrosis? What do we know and what do we have to learn?].
Ortega LM; Contreras G; Lenz O
Nefrologia; 2009; 29(2):109-17. PubMed ID: 19396315
[TBL] [Abstract][Full Text] [Related]
25. Gadolinium Retention and Breast MRI Screening: More Harm Than Good?
Sardanelli F; Cozzi A; Trimboli RM; Schiaffino S
AJR Am J Roentgenol; 2020 Feb; 214(2):324-327. PubMed ID: 31799869
[No Abstract] [Full Text] [Related]
26. Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution.
Do C; DeAguero J; Brearley A; Trejo X; Howard T; Escobar GP; Wagner B
Kidney360; 2020 Jun; 1(6):561-568. PubMed ID: 34423308
[TBL] [Abstract][Full Text] [Related]
27. Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media.
Canga A; Kislikova M; Martínez-Gálvez M; Arias M; Fraga-Rivas P; Poyatos C; de Francisco AL
Nefrologia; 2014; 34(4):428-38. PubMed ID: 25036056
[TBL] [Abstract][Full Text] [Related]
28. Exposure of Macrophages to Low-Dose Gadolinium-Based Contrast Medium: Impact on Oxidative Stress and Cytokines Production.
Weng TI; Chen HJ; Lu CW; Ho YC; Wu JL; Liu SH; Hsiao JK
Contrast Media Mol Imaging; 2018; 2018():3535769. PubMed ID: 30627059
[TBL] [Abstract][Full Text] [Related]
29. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
[TBL] [Abstract][Full Text] [Related]
30. Is it safe to use gadolinium-based contrast agents in MRI?
Pullicino R; Das K
J R Coll Physicians Edinb; 2017 Sep; 47(3):243-246. PubMed ID: 29465099
[TBL] [Abstract][Full Text] [Related]
31. Gadolinium-based contrast agents in children.
Rozenfeld MN; Podberesky DJ
Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
[TBL] [Abstract][Full Text] [Related]
32. Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging.
Holowka S; Shroff M; Chavhan GB
Indian J Pediatr; 2019 Oct; 86(10):961-966. PubMed ID: 30796704
[TBL] [Abstract][Full Text] [Related]
33. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study.
Amet S; Launay-Vacher V; Clément O; Frances C; Tricotel A; Stengel B; Gauvrit JY; Grenier N; Reinhardt G; Janus N; Choukroun G; Laville M; Deray G
Invest Radiol; 2014 Feb; 49(2):109-15. PubMed ID: 24169070
[TBL] [Abstract][Full Text] [Related]
34. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
[TBL] [Abstract][Full Text] [Related]
35. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
[TBL] [Abstract][Full Text] [Related]
36. Gadolinium toxicity: Iron and ferroportin as central targets.
Swaminathan S
Magn Reson Imaging; 2016 Dec; 34(10):1373-1376. PubMed ID: 27580520
[TBL] [Abstract][Full Text] [Related]
37. Nephrogenic systemic fibrosis: a concise review for cardiologists.
Cheong BY; Muthupillai R
Tex Heart Inst J; 2010; 37(5):508-15. PubMed ID: 20978560
[TBL] [Abstract][Full Text] [Related]
38. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure].
Mundim JS; Lorena Sde C; Abensur H; Elias RM; Moysés RM; Castro MC; Romão Júnior JE
Rev Assoc Med Bras (1992); 2009; 55(2):220-5. PubMed ID: 19488662
[TBL] [Abstract][Full Text] [Related]
39. Nephrogenic systemic fibrosis: a report of 29 cases.
Shabana WM; Cohan RH; Ellis JH; Hussain HK; Francis IR; Su LD; Mukherji SK; Swartz RD
AJR Am J Roentgenol; 2008 Mar; 190(3):736-41. PubMed ID: 18287446
[TBL] [Abstract][Full Text] [Related]
40. Neutrophil elastase in the development of nephrogenic systemic fibrosis (NSF)-like skin lesion in renal failure mouse model.
Kartamihardja AAP; Amalia SN; Sekiguchi A; Bhattarai A; Taketomi-Takahashi A; Motegi SI; Koyama H; Tsushima Y
PLoS One; 2021; 16(10):e0259211. PubMed ID: 34705860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
